Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

The drug, gedatolisib, in combination with Pfizer's Ibrance and AstraZeneca's endocrine therapy Faslodex, reduced the risk of ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

Early-onset GI cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced ...

Celcuity shares soar 186% after Phase 3 breast cancer trial shows triple therapy delays disease by over 7 months.

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

By Mariam Sunny (Reuters) -Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's ...